CRAFA
PEPTIDE & COMPOUND ANALYSIS

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-1079
Issued: 2026-10-05

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

PRODUCT IDENTIFICATION

PRODUCT Tesamorelin	SKU / INTERNAL CODE CRF-TESAMORELIN	PRESENTATION Lyophilised powder, 5 mg vial
BATCH NUMBER LOT-2610-079	SAMPLE RECEIVED 2026-09-28	PRODUCTION DATE 2026-09-25
ANALYSIS DATE 2026-10-03	EXPIRY / RETEST DATE 2028-10-03	MOLECULAR FORMULA (REFERENCE) C221H366N72O67S
MOLECULAR WEIGHT (G/MOL; REFERENCE) 5135.9	CAS (REFERENCE) 218949-48-5	

Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.

ANALYTICAL METHOD — HPLC

INSTRUMENT Waters Xevo G3	COLUMN C4 2.1×100mm	COLUMN TEMPERATURE 60°C
MOBILE PHASE A 0.1% TFA H2O	MOBILE PHASE B ACN	FLOW RATE 0.3 mL/min
DETECTION WAVELENGTH 214 nm	INJECTION VOLUME 5 µL	SAMPLE CONCENTRATION 0.5 mg/mL
DILUENT —	RETENTION TIME (MAIN PEAK) 13.1 min	

Recorded methods: HPLC-UV (214 nm) · LC-MS/MS · LAL · ICP-MS

RESULTS

Test	Acceptance Criteria	Result	Verdict
HPLC Purity (% area)	≥98.0%	99.2%	PASS
Identity (LC-MS)	5136.9 ±2%	Obs: 5137.3 [M+H]+	PASS
Quantity found	95.0–105.0%	4.96 mg (99.2%)	PASS
Endotoxin	<1.0 EU/mg	<0.5 EU/mg	PASS
Heavy metals	<10 ppm	All <LOQ	PASS

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: 44-amino acid sequence verified, acetate salt form.

crafa

CRAFA